Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

View

blood_cancer_j_2023-33.pdf (756.4Kb)

Identifiers

URI: https://hdl.handle.net/20.500.13003/18923

DOI: 10.1038/s41408-023-00805-x

eISSN: 2044-5385

WOS ID: 000950825100001

Scopus EID: 2-s2.0-85149595607

PMID: 36882409

Embase PUI: L2021978120

Metrics

10.1038/s41408-023-00805-x

 

 

Share

Export

External links

Statistics

Item usage statistics

Metadata

Show Dublin Core item record

Author

Moreau, Philippe; Chari, Ajai; Oriol, Albert; Martinez-Lopez, Joaquin; Haenel, Mathias; Touzeau, Cyrille; Ailawadhi, Sikander; Besemer, Britta; de la Rubia Comos, Javier; Encinas, Cristina; Mateos, Maria-Victoria; Salwender, Hans; Rodriguez-Otero, Paula; Hulin, Cyrille; Karlin, Lionel; Sureda Balari, Anna; Bargay Lleonart, Joan ; Benboubker, Lotfi; Rosiñol, Laura; Tarantolo, Stefano; Terebelo, Howard; Yang, Shiyi; Wang, Jianping; Nnane, Ivo; Qi, Ming; Kosh, Michele; Delioukina, Maria; Goldschmidt, Hartmut

Publication date

2023-03-07

Document type

letter to the editor

Citation

Moreau P, Chari A, Oriol A, Martinez-Lopez J, Haenel M, Touzeau C, et al. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood Cancer J. 2023 Mar 7;13(1):33.

Publisher version

https://doi.org/10.1038/s41408-023-00805-x

MeSH

Multiple Myeloma
Antibodies, Monoclonal
Humans
Neoplasms, Plasma Cell
Dexamethasone

DeCS

Dexametasona
Humanos
Neoplasias de Células Plasmáticas
Mieloma Múltiple
Anticuerpos Monoclonales

This item appears in following Docusalut collections

Instituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científica
Hospital Universitario Son Llàtzer - HUSLL > Comunicación científica